Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qing Xi Ooi

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|December 13, 2024
A tutorial on pharmacometric Markov modelsQing Xi Ooi, Elodie Plan, Martin Bergstrand
British Journal of Clinical Pharmacology|November 16, 2019
Kinetic-pharmacodynamic model for drugs with non-linear elimination: Parameterisation mattersQing Xi Ooi, Chihiro Hasegawa, Stephen B Duffull, et al.
Scientific Reports|August 15, 2018
A factor VII-based method for the prediction of anticoagulant response to warfarinQing-Xi Ooi, Daniel F B Wright, Geoffrey K Isbister, et al.
The AAPS Journal|August 7, 2019
Evaluation of Assumptions Underpinning Pharmacometric ModelsQing-Xi Ooi, Daniel F B Wright, Geoffrey K Isbister, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 15, 2023
Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357Qing Xi Ooi, Anders Kristoffersson, Julia Korell, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 20, 2026
Population Pharmacokinetics and Pharmacokinetics-Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary CholangitisQing Xi Ooi, Karl Brendel, Stijn van Beek, et al.
Clinical Pharmacokinetics|April 15, 2017
A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation ProteinsQing Xi Ooi, Daniel F B Wright, R Campbell Tait, et al.
British Journal of Clinical Pharmacology|August 17, 2022
Assessment of the nlmixr R package for population pharmacokinetic modeling: A metformin case studyWen Yao Mak, Qing Xi Ooi, Cintia Valeria Cruz, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 4, 2022
Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarityRobin J Svensson, Qing Xi Ooi, Lena E Friberg, et al.
Clinical and Translational Science|December 28, 2021
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetesYoshiko Tomita, Emma Hansson, Florent Mazuir, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|December 13, 2024
A tutorial on pharmacometric Markov modelsQing Xi Ooi, Elodie Plan, Martin Bergstrand
British Journal of Clinical Pharmacology|November 16, 2019
Kinetic-pharmacodynamic model for drugs with non-linear elimination: Parameterisation mattersQing Xi Ooi, Chihiro Hasegawa, Stephen B Duffull, et al.
Scientific Reports|August 15, 2018
A factor VII-based method for the prediction of anticoagulant response to warfarinQing-Xi Ooi, Daniel F B Wright, Geoffrey K Isbister, et al.
The AAPS Journal|August 7, 2019
Evaluation of Assumptions Underpinning Pharmacometric ModelsQing-Xi Ooi, Daniel F B Wright, Geoffrey K Isbister, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 15, 2023
Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357Qing Xi Ooi, Anders Kristoffersson, Julia Korell, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 20, 2026
Population Pharmacokinetics and Pharmacokinetics-Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary CholangitisQing Xi Ooi, Karl Brendel, Stijn van Beek, et al.
Clinical Pharmacokinetics|April 15, 2017
A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation ProteinsQing Xi Ooi, Daniel F B Wright, R Campbell Tait, et al.
British Journal of Clinical Pharmacology|August 17, 2022
Assessment of the nlmixr R package for population pharmacokinetic modeling: A metformin case studyWen Yao Mak, Qing Xi Ooi, Cintia Valeria Cruz, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 4, 2022
Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarityRobin J Svensson, Qing Xi Ooi, Lena E Friberg, et al.
Clinical and Translational Science|December 28, 2021
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetesYoshiko Tomita, Emma Hansson, Florent Mazuir, et al.
Pageof 1